Michael Chambers & John Ballantyne, Aldevron co-founders
May 16, 2022 01:28 PM EDTUpdated 04:06 PM
Deals
R&D
Pharma

Alde­vron and In­scrip­ta ink man­u­fac­tur­ing deal for CRISPR Type-V nu­cle­ase

Tyler Patchen

News Reporter

A plan to broad­en ac­cess to CRISPR has at­tract­ed a chunk of fund­ing and is now see­ing its wings spread.

Far­go-based DNA and mR­NA pro­duc­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

What will phar­ma's share buy­back shop­ping spree mean for M&A?

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times